Evaxion Biotech A/S (EVAX)
Market Closed
17 Jan, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
3. 09
-0.27
-8.04%
$
9.68M Market Cap
- P/E Ratio
0% Div Yield
59,400 Volume
- Eps
$ 3.36
Previous Close Day Range
3.03 3.49
Year Range
0.83 13.61
Earnings results expected in 63 days
Summary
EVAX closed Friday lower at $3.09, a decrease of 8.04% from Thursday's close, completing a monthly increase of 259.3% or $2.23. Over the past 12 months, EVAX stock gained 259.3%.
EVAX is not paying dividends to its shareholders.
The last earnings report, released on Dec 17, 2024, exceeded the consensus estimates by 0.31%. On average, the company has surpassed earnings expectations by 0.32%, based on the last three reports. The next scheduled earnings report is due on Mar 25, 2025.
Evaxion Biotech A/S has completed 3 stock splits, with the recent split occurring on Jan 14, 2025.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
Want to track EVAX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
EVAX Chart
FAQ
What Is the Evaxion Biotech A/S(EVAX) Stock Price Today?
The EVAX stock price today is $3.09.
What Stock Exchange Does Evaxion Biotech A/S Trade On?
Evaxion Biotech A/S is listed and trades on the NASDAQ (CM).
What Is the Stock Symbol for Evaxion Biotech A/S?
The stock symbol for Evaxion Biotech A/S is "EVAX".
Does Evaxion Biotech A/S Pay Dividends? What's The Current Dividend Yield?
EVAX is not paying dividends to its shareholders.
What Is the Evaxion Biotech A/S Market Cap?
As of today, Evaxion Biotech A/S market cap is 9.68M.
What is Evaxion Biotech A/S Earnings Per Share?
The Evaxion Biotech A/S EPS is 0.
What Is the Next Evaxion Biotech A/S Earnings Date?
Evaxion Biotech A/S will release its next earnings report on Mar 25, 2025.
Did Evaxion Biotech A/S had any splits?
Evaxion Biotech A/S had 3 splits and the recent split was on Jan 14, 2025.
Evaxion Biotech A/S Profile
| Biotechnology Industry | Healthcare Sector | - CEO | NASDAQ (CM) Exchange | US29970R1059 ISIN |
| Denmark Country | 49 Employees | - Last Dividend | 22 Jan 2024 Last Split | - IPO Date |
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Contact Information
Address: Dr. Neergaards Vej
Phone: 45 31 31 97 53
Website: https://www.evaxion-biotech.com
2025 © Marketlog. All Rights Reserved.
